{"filings":[{"id":2033357,"accession_number":"0001104659-26-090045","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-08-04T10:47:58+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q2 2026: GAAP loss $0.54 on $16.6B sales; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total worldwide sales $16.6B, up 5% (4% ex-FX); KEYTRUDA/KEYTRUDA QLEX sales $8.4B (+5%).","GAAP loss per share $0.54; non-GAAP loss per share $0.13; both include $2.31/share charge for Terns acquisition.","Full-year 2026 guidance: sales range raised to $66.3B-$67.3B; non-GAAP EPS $2.66-$2.76 (includes $2.43/share Terns charge).","FDA approved LIPFENDRA (enlicitide), first once-daily oral PCSK9 inhibitor for hypercholesterolemia.","Completed acquisition of Terns for $6.8B; added MK-4208 (BCR::ABL1 inhibitor) to pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":722209,"accession_number":"0001104659-26-067509","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-05-28T20:15:25+00:00","items":["5.07"],"status":"ready","headline":"Merck shareholders elect all 13 directors, approve say-on-pay, reject three proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; Patricia Russo received 1.637B for (highest opposition at 217M votes against).","Say-on-pay passed: 1.730B for, 109M against, 284M broker non-votes.","Ratification of PwC as auditor for 2026 approved: 2.012B for, 126M against.","Three shareholder proposals on DEI risks, healthcare gaps, political contributions all rejected; each received <5% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609956,"accession_number":"0001628280-26-037738","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-05-22T20:21:18+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck closes $6B multi-tranche debt offering with maturities from 2028 to 2056","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $6B aggregate principal across seven tranches: floating rate notes due 2028 and fixed-rate notes at 4.300%-5.850% due 2028-2056.","Tranches include $1.5B 5.200% notes due 2036 and $1B 5.850% notes due 2056.","Offering closed May 22, 2026 via underwritten public offering under existing shelf registration.","Use of proceeds not disclosed; debt issuance adds to long-term balance sheet leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97890,"accession_number":"0001104659-26-052081","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck reports Q1 GAAP loss per share of $1.72 on $16.3B sales; narrows and raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS loss of $1.72; Non-GAAP EPS loss of $1.28, both include $3.62/share charge for Cidara acquisition.","Total sales $16.3B, +5% YoY; KEYTRUDA sales $8.0B (+12%), WINREVAIR $525M (+88%).","Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS guidance raised to $5.04-$5.16.","Announced agreement to acquire Terns Pharmaceuticals; one-time charge ~$5.8B (~$2.35/share) not in guidance.","Animal Health sales $1.8B (+13%); multiple regulatory approvals including IDVYNSO for HIV."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":16286000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113075,"accession_number":"0001104659-26-009495","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).","Full-year sales $65.0B; Non-GAAP EPS $8.98 (+17% YoY).","KEYTRUDA $31.7B (+7%); WINREVAIR $1.4B; GARDASIL $5.2B (-39% on China weakness).","FY2026 sales guidance $65.5-$67.0B; Non-GAAP EPS $5.00-$5.15 includes ~$3.65 Cidara charge.","Acquired Verona Pharma and Cidara; 18 positive Phase 3 trials in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":7.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":65011000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129479,"accession_number":"0001628280-25-055388","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck closes $8.0B multi-tranche debt offering across eight series","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total $8.0B includes Floating Rate Notes due 2029 ($500M), 3.850% Notes due 2029 ($750M), 4.150% due 2031 ($1B), 4.450% due 2032 ($1B).","Also $1.5B 4.750% Notes due 2035, $750M 5.500% due 2046, $1.5B 5.550% due 2055, and $1.0B 5.700% due 2065.","Offering closed December 4, 2025 under existing shelf registration statement (333-278066).","Proceeds not specified; notes are senior unsecured obligations issued under indenture dated Jan. 6, 2010."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129478,"accession_number":"0001104659-25-103974","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.","KEYTRUDA sales $8.1B (+10%); WINREVAIR $360M (+141%); GARDASIL down 24% to $1.7B.","Full-year 2025 sales guidance raised to $64.5-65.0B; non-GAAP EPS raised to $8.93-8.98.","Completed acquisition of Verona Pharma (OHTUVAYRE) in October 2025.","FDA approved KEYTRUDA QLEX subcutaneous injection for all solid tumor indications."],"consensus_eps_estimate":null,"consensus_eps_actual":6.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":48611000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146044,"accession_number":"0000310158-25-000047","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck closes $6B multi-tranche debt offering: floating-rate notes due 2027 to 5.700% notes due 2055","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offered $500M floating rate notes due 2027, $750M 3.850% notes due 2027, $750M 4.150% notes due 2030.","Offered $1B 4.550% notes due 2032, $1.75B 4.950% notes due 2035, $1.25B 5.700% notes due 2055.","Total aggregate principal amount of the offering is $6 billion, closed on September 9, 2025.","Proceeds use not specified; offering was underwritten public under existing shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146043,"accession_number":"0001104659-25-071380","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Merck reports Q2 2025 sales of $15.8B, down 2%, and announces $3B restructuring program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total worldwide sales $15.8 billion, down 2% nominally and ex-forex vs Q2 2024; KEYTRUDA sales $8.0 billion, up 9%.","GAAP EPS $1.76, Non-GAAP EPS $2.13; includes $0.07 per share charge for Hengrui Pharma license agreement.","GARDASIL/GARDASIL 9 sales $1.1 billion, decline of 55% primarily due to lower demand in China.","Approved 2025 Restructuring Program with cumulative pretax cost ~$3.0 billion, expected annual savings ~$1.7 billion by end of 2027.","Announced agreement to acquire Verona Pharma for ~$10 billion, adding COPD treatment Ohtuvayre; expected close Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":3.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":31335000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164346,"accession_number":"0001104659-25-054131","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Merck shareholders re-elect all 13 directors, defeat four shareholder proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; Patricia Russo received lowest support with 1.59B for and 250.6M against.","Non-binding say-on-pay passed with 1.67B votes for (84.8% of votes cast excluding broker non-votes).","Ratification of PricewaterhouseCoopers as auditor for 2025 approved with 2.02B votes for.","Shareholder proposals on human rights assessment, tax transparency, DEI in pay incentives, and civil liberties report all defeated by large margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164345,"accession_number":"0001104659-25-038301","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck reports Q1 2025 EPS $2.01, sales $15.5B; GARDASIL plunges 41% on China weakness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $2.01 (up 7% YoY); non-GAAP EPS $2.22 (up 7%); revenue $15.5B (-2% reported, +1% ex-FX).","KEYTRUDA sales $7.2B (+4% reported, +6% ex-FX); WINREVAIR $280M post-launch; Animal Health +5%.","GARDASIL sales fell 41% to $1.3B on lower China demand; ex-China sales grew 14% (16% ex-FX).","FY2025 non-GAAP EPS guidance revised to $8.82-8.97 from $8.88-9.03 due to $0.06 charge for Hengrui license.","Tariffs expected to add ~$200M cost in 2025; full-year sales outlook unchanged at $64.1B-$65.6B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":15529000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182102,"accession_number":"0001104659-25-008863","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q4 2024 sales $15.6B (+7% YoY); GAAP EPS $1.48, Non-GAAP $1.72; FY2025 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 worldwide sales $64.2B (+7% YoY; +10% ex-FX).","Q4 GAAP EPS $1.48; Non-GAAP EPS $1.72 (includes $0.23 charge for licensing).","KEYTRUDA full-year sales $29.5B (+18% YoY; +22% ex-FX).","WINREVAIR full-year sales $419M; GARDASIL declined 3% to $8.6B on lower China demand.","FY2025 guidance: sales $64.1-65.6B; Non-GAAP EPS $8.88-9.03 (incl. ~$0.09 LaNova charge)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":64168000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198758,"accession_number":"0001104659-24-122027","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Lal Karsanbhai (Emerson CEO) elected to Merck board; effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lal Karsanbhai, president and CEO of Emerson Electric, elected to Merck board effective January 1, 2025.","He will serve on Audit and Governance committees and stand for election at May 2025 shareholder meeting.","Merck board expands to 13 members with addition; compensation per non-employee director practices.","Board also adopted amended by-laws updating indemnification provisions; other non-substantive changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198757,"accession_number":"0001104659-24-112841","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q3 2024: GAAP EPS $1.24, Non-GAAP $1.57; Sales $16.7B (+4% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total worldwide sales $16.7B, up 4% (7% ex-FX). GAAP EPS $1.24; Non-GAAP EPS $1.57.","KEYTRUDA sales $7.4B (+17% / 21% ex-FX). WINREVAIR sales $149M, gaining momentum.","FY2024 guidance narrowed: sales $63.6B-$64.1B; Non-GAAP EPS $7.72-$7.77, includes $0.24/share net charge from Curon and Daiichi Sankyo deals.","R&D expenses surged 77% to $5.9B, driven by $1.35B EyeBio acquisition and $750M Curon asset purchase.","GARDASIL/GARDASIL 9 sales fell 11% due to lower China demand; Animal Health up 6% (11% ex-FX)."],"consensus_eps_estimate":null,"consensus_eps_actual":5.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":48544000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214793,"accession_number":"0001104659-24-083722","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q2 2024: revenue $16.1B (+7% YoY); raises sales outlook but lowers EPS guidance on EyeBio charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $16.1B (+7% YoY, +11% ex-FX); GAAP EPS $2.14, Non-GAAP EPS $2.28; KEYTRUDA sales $7.3B (+16%).","Full-year 2024 sales outlook raised to $63.4-64.4B (from $63.1-64.3B); Non-GAAP EPS guidance lowered to $7.94-8.04 (from $8.53-8.65) due to $1.3B EyeBio acquisition charge.","WINREVAIR generated $70M in Q2 sales; over 1,000 patients treated since U.S. launch in March 2024.","Completed acquisitions of EyeBio and Elanco's Aqua Business in July 2024; $0.51/share EPS impact from EyeBio.","CDC's ACIP unanimously recommended CAPVAXIVE; positive EU CHMP opinion for WINREVAIR in PAH."],"consensus_eps_estimate":null,"consensus_eps_actual":4.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":31887000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233937,"accession_number":"0001628280-24-025800","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Merck subsidiary MSD Netherlands closes €3.4B offering of senior notes across four tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€850M each of 3.250% notes due 2032, 3.500% notes due 2037, 3.700% notes due 2044, 3.750% notes due 2054.","Notes are fully and unconditionally guaranteed on an unsecured senior basis by Merck & Co., Inc.","All 12 director nominees elected with 84.78%-99.49% of votes cast; advisory say-on-pay approved at 93.50%.","Shareholder proposals on written consent, censorship, and workforce civil liberties all defeated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233936,"accession_number":"0001104659-24-051517","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q1 sales up 9% to $15.8B; raises FY2024 sales and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $1.87 (+68% YoY); Non-GAAP EPS $2.07 (+48% YoY). Sales $15.775B (+9%, +12% ex-FX).","Keytruda sales grew 20% to $6.9B; Gardasil sales up 14% to $2.2B on strong China demand.","Full-year 2024 sales outlook raised to $63.1-$64.3B; Non-GAAP EPS outlook raised to $8.53-$8.65.","Received FDA approval for WINREVAIR (PAH); closed Harpoon acquisition with $656M charge.","Proposed acquisition of Elanco's aqua business to broaden animal health portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":15775000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251918,"accession_number":"0001104659-24-025524","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Peter C. Wendell to retire from Merck board at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter C. Wendell notified Merck on Feb 15, 2024, of his retirement from the board.","Retirement effective as of the 2024 Annual Meeting of Shareholders on May 28, 2024.","Retirement is not due to any disagreement with Merck regarding operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251917,"accession_number":"0001104659-24-009109","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Merck reports Q4 GAAP loss of $0.48/share; plans $4B restructuring; FY2024 EPS guidance $8.44-8.59","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 GAAP net loss $1.2B ($0.48 loss per share); non-GAAP EPS $0.03, includes $1.69/share Daiichi Sankyo charge.","Full-year 2023 sales $60.1B (+1% YoY); KEYTRUDA $25B (+19%), GARDASIL $8.9B (+29%), LAGEVRIO down 75% to $1.4B.","FY 2024 outlook: sales $62.7-64.2B; non-GAAP EPS $8.44-8.59.","Approved 2024 Restructuring Program with cumulative pretax costs ~$4B; ~60% non-cash; substantially complete by end of 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":60115000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269445,"accession_number":"0001104659-23-121671","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Merck appoints Dalton Smart III as principal accounting officer, succeeding Rita Karachun","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rita Karachun, principal accounting officer, resigns effective Dec 4, 2023; plans to retire in 2024.","Dalton E. Smart III appointed Senior VP Finance – Global Controller and principal accounting officer, effective Dec 4, 2023.","Smart previously served as Assistant Controller since Sep 2023 and VP Internal Audit from Mar 2015 to Aug 2023.","Resignation not due to any disagreement with company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269444,"accession_number":"0001104659-23-111585","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q3 revenue $16.0B (+7%), KEYTRUDA up 17%; cuts FY EPS guidance on $5.5B Daiichi Sankyo charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total sales $16.0B (+7% YoY); GAAP EPS $1.86, Non-GAAP EPS $2.13 (+15% YoY).","KEYTRUDA sales $6.3B (+17%); GARDASIL/GARDASIL 9 sales $2.6B (+13%).","Full-year 2023 sales guidance raised to $59.7-$60.2B; Non-GAAP EPS guidance lowered to $1.33-$1.38 due to $5.5B upfront charge from Daiichi Sankyo collaboration.","Entered collaboration with Daiichi Sankyo for three clinical-stage ADC candidates; upfront payment $5.5B.","FDA approved KEYTRUDA for perioperative NSCLC; priority review for sotatercept (PDUFA March 26, 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":45485000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286420,"accession_number":"0001104659-23-086030","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck posts Q2 GAAP loss of $5.98B on $10.2B Prometheus charge; raises FY sales outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP loss per share of $2.35 on net loss of $5,975M; includes $4.02/share charge for Prometheus acquisition.","Total sales $15,035M (+3% YoY); excluding LAGEVRIO, sales grew 11% (+14% ex-FX).","KEYTRUDA sales $6,271M (+19% YoY); GARDASIL/GARDASIL 9 sales $2,458M (+47% YoY).","LAGEVRIO sales fell 83% to $203M; non-GAAP EPS loss of $2.06 vs. $1.87 gain a year ago.","FY 2023 sales outlook raised to $58.6-59.6B; non-GAAP EPS outlook $2.95-3.05 (includes -$4.53/share one-time charges)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":29522000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306306,"accession_number":"0001140361-23-026845","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Merck shareholders elect 13 directors; say-on-pay passes with 91.3% support","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected with 86.11% to 99.40% votes cast in favor.","Non-binding say-on-pay passed with 91.30% of votes cast; frequency vote favored 1 year (99.98%).","Ratification of auditor approved with 94.27% votes cast in favor.","All five shareholder proposals failed, highest support 32.42% (independent chair)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306305,"accession_number":"0001193125-23-147049","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck closes $6B multi-tranche debt offering across six maturities from 2028 to 2063","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M 4.050% Notes due 2028, $750M 4.300% Notes due 2030, $1.5B 4.500% Notes due 2033, $750M 4.900% Notes due 2044, $1.5B 5.000% Notes due 2053, $1B 5.150% Notes due 2063.","Total aggregate principal amount of $6.0B issued in underwritten public offering.","Offering closed on May 17, 2023.","Notes issued under indenture with U.S. Bank Trust; legal opinion and officers' certificates filed as exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306304,"accession_number":"0001104659-23-050654","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q1 revenue $14.5B (-9%), GAAP EPS $1.11; raises FY non-GAAP EPS guidance to $6.88-$7.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $14.5B, down 9% YoY; excluding LAGEVRIO and FX, up 15%.","GAAP EPS $1.11, Non-GAAP EPS $1.40; both down 35% YoY.","KEYTRUDA sales $5.8B (+20%), GARDASIL sales $2.0B (+35% YoY).","LAGEVRIO sales fell 88% to $392M; proposed Prometheus acquisition for $10.8B expected Q3 2023.","FY2023 outlook raised: sales $57.7-$58.9B, Non-GAAP EPS $6.88-$7.00; GAAP EPS lowered to $5.85-$5.97 on Zetia settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":14487000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325473,"accession_number":"0001104659-23-009552","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q4 GAAP EPS $1.18, revenue $13.8B; guides FY2023 non-GAAP EPS $6.80-$6.95","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 GAAP EPS $1.18 (down 22% YoY); non-GAAP EPS $1.62 (down 10%); revenue $13.8B (+2%, +8% ex-FX).","Full-year 2022 sales $59.3B (+22% YoY); KEYTRUDA $20.9B (+22%); GARDASIL $6.9B (+22%).","FY2023 guidance: sales $57.2B-$58.7B (incl. ~$1B LAGEVRIO); GAAP EPS $5.86-$6.01; non-GAAP EPS $6.80-$6.95.","Completed Imago BioSciences acquisition for $1.35B; new ADC collaboration with Kelun-Biotech.","Regulatory: KEYTRUDA approved for adjuvant NSCLC; positive KEYNOTE-859 (gastric) and KEYNOTE-966 (biliary) data."],"consensus_eps_estimate":null,"consensus_eps_actual":5.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":59283000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343217,"accession_number":"0001104659-22-111729","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Merck Q3 beats: rev $15B, non-GAAP EPS $1.85; raises FY outlook; Davis to become Chairman","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $15.0B (+14% YoY); GAAP EPS $1.28, non-GAAP EPS $1.85 (+4% from $1.78).","KEYTRUDA sales $5.4B (+20%), GARDASIL sales $2.3B (+15%); LAGEVRIO contributed $436M.","Raises FY2022 sales outlook to $58.5-59.0B (growth 20-21%); non-GAAP EPS guidance raised to $7.32-7.37.","Executive Chairman Kenneth Frazier to retire Nov 30; CEO Robert Davis elected Chairman effective Dec 1."],"consensus_eps_estimate":null,"consensus_eps_actual":4.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":45453000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359766,"accession_number":"0001104659-22-083410","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q2 revenue up 28% to $14.6B; non-GAAP EPS $1.87 vs $0.61; raises 2022 sales guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KEYTRUDA sales rose 26% to $5.3B; GARDASIL/GARDASIL 9 up 36% to $1.7B, driven by China demand.","LAGEVRIO contributed $1.2B in Q2 sales; full-year outlook maintained at $5.0-$5.5B.","GAAP EPS $1.55 vs $0.48; non-GAAP EPS $1.87 vs $0.61, reflecting strong operational performance.","Company raised and narrowed 2022 full-year sales guidance to $57.5-$58.5B (18-20% growth).","Non-GAAP EPS guidance narrowed to $7.25-$7.35; includes ~$0.09 impact from Orion upfront payment."],"consensus_eps_estimate":null,"consensus_eps_actual":3.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":30494000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378595,"accession_number":"0000310158-22-000015","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Merck annual meeting: directors elected, say-on-pay approved, three shareholder proposals defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 14 director nominees elected; Patricia F. Russo received the most votes against (250.9M), but still won.","Advisory vote on executive compensation approved with 1.64B for vs 144.7M against.","Ratification of independent auditor approved: 2.03B for, 83.7M against.","Shareholder proposals on independent board chair, COVID-19 access, and lobbying disclosure all defeated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378594,"accession_number":"0001104659-22-051588","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q1 sales $15.9B (+50% YoY); Non-GAAP EPS $2.14; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $15.9B, +50% YoY (52% ex-FX); KEYTRUDA $4.8B (+23%), LAGEVRIO contributed $3.2B.","GAAP EPS $1.70 vs $1.08; Non-GAAP EPS $2.14 vs $1.16, both well above prior year.","Raises 2022 sales guidance to $56.9-$58.1B (17-19% growth); Non-GAAP EPS guidance $7.24-$7.36.","JANUVIA/JANUMET sales fell 5% to $1.2B; expect loss of EU/China exclusivity in Q3 2022.","Pipeline progress: FDA approvals for KEYTRUDA in MSI-H endometrial cancer and Lynparza in adjuvant breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":1.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":15901000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378593,"accession_number":"0001104659-22-047977","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Merck ends exclusion of upfront/milestone payments and pre-approval asset charges from non-GAAP results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merck will no longer exclude upfront/milestone payments and pre-approval asset acquisition charges from non-GAAP results, effective Q1 2022.","Recast FY2021 non-GAAP EPS from continuing ops is $5.37, down from previously reported $6.02; FY2020 revised to $2.97 from $4.53.","Change aligns with SEC staff views; does not affect Q1 2021 or Q1 2022 non-GAAP results.","Revised non-GAAP R&D expense for full-year 2021 is $11,738M vs previously reported $10,077M (increase of $1,661M).","The recast 2021 annual net income attributable to Merck is $13,623M vs previously $15,282M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396865,"accession_number":"0000310158-22-000006","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2022-03-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Merck amends by-laws to allow remote shareholder meetings under New Jersey law","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended by-laws on March 22, 2022, effective immediately.","Amendment reflects recent change to NJ Business Corporation Act permitting remote communication meetings.","No other changes to by-laws or corporate governance structure were made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396864,"accession_number":"0001104659-22-011130","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q4 2021 revenue $13.5B (+24%), Non-GAAP EPS $1.80; FY2022 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 sales $13.5B (+24% YoY); GAAP EPS $1.51, Non-GAAP EPS $1.80 (vs $0.98).","Full-year 2021 sales $48.7B (+17%); GAAP EPS $4.86, Non-GAAP EPS $6.02.","KEYTRUDA FY sales $17.2B (+20%); GARDASIL/GARDASIL 9 sales $5.7B (+44%).","Molnupiravir contributed $952M in Q4; Animal Health sales $5.6B (+18%).","FY2022 guidance: sales $56.1-$57.6B, GAAP EPS $5.76-$5.91, Non-GAAP EPS $7.12-$7.27."],"consensus_eps_estimate":null,"consensus_eps_actual":5.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":48704000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415823,"accession_number":"0001193125-21-354132","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2021-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck raises $8.0B via multi-tranche note offering (1.700%-2.900% maturities 2027-2061)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Dec 10, 2021, closed underwritten public offering of $8.0B aggregate principal amount of senior notes.","Tranches: $1.5B 1.700% notes due 2027, $1.0B 1.900% notes due 2028, $2.0B 2.150% notes due 2031.","Also $2.0B 2.750% notes due 2051 and $1.5B 2.900% notes due 2061.","Notes issued under indenture dated Jan 6, 2010 with U.S. Bank Trust National Association as trustee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415822,"accession_number":"0001104659-21-130675","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q3 sales $13.2B (+20% YoY); raises FY2021 guidance; to acquire Acceleron for $11.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP EPS $1.80, Non-GAAP EPS $1.75; sales $13.2B (+20% YoY, +19% ex-FX).","Keytruda sales $4.5B (+22%); Gardasil $2.0B (+68%); Animal Health $1.4B (+16%).","Raises FY2021 revenue guidance to $47.4B–$47.9B; Non-GAAP EPS to $5.65–$5.70.","Agreement to acquire Acceleron Pharma for $180/share (~$11.5B); expected close Q4 2021.","Submitted EUA for molnupiravir (oral COVID-19 treatment) based on positive Phase 3 data."],"consensus_eps_estimate":null,"consensus_eps_actual":3.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":35183000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433429,"accession_number":"0001140361-21-029043","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2021-08-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Independent Lead Director Leslie A. Brun resigns from Merck board to lead Ariel Alternatives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leslie A. Brun resigned from Merck's Board of Directors effective August 19, 2021.","Brun stepped down to become chairman and CEO of Ariel Alternatives, a private equity initiative of Ariel Investments.","Merck is evaluating making an investment in Ariel Alternatives.","Merck intends to name a new independent lead director in the near future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433428,"accession_number":"0001104659-21-097239","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q2 sales $11.4B (+22% YoY); raises full-year revenue guidance to $46.4B-$47.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.48; non-GAAP EPS $1.31, up 28% YoY on strong demand recovery.","KEYTRUDA sales $4.2B (+23%); GARDASIL $1.2B (+88%) driven by pandemic recovery.","Completed Organon spinoff on June 2; received ~$9B cash distribution.","Full-year non-GAAP EPS guidance raised to $5.47-$5.57, including ~2% FX benefit.","FDA approvals for VAXNEUVANCE, KEYTRUDA in TNBC and endometrial carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":22029000000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}